Scientists have established the first internationally coordinated clinical guidelines for personalized phage therapy, a treatment approach that uses bacteria-killing viruses to combat infections resistant to conventional antibiotics. The consensus statement, published in the journal Nature Medicine, provides a unified framework for doctors and researchers to safely incorporate these viruses into medical practice.
The effort was led by the German Society for Infectious Diseases (DGI). It involved 20 professional organizations, 18 international experts from regulatory agencies, and two patient advocacy groups. Together, they developed more than 60 recommendations covering the selection, testing, manufacturing, administration, and monitoring of phages.
Addressing Antibiotic Resistance with Precision
Antibiotic resistance is making bacterial infections increasingly difficult to treat worldwide. As bacteria develop defenses against common medications, doctors often face limited options. Phage therapy offers a potential alternative. Bacteriophages, or phages, are viruses that naturally infect and destroy specific bacteria.
Unlike broad-spectrum antibiotics, phages typically target particular bacterial species or even individual strains. This precision is advantageous but creates a logistical challenge. A virus effective against one strain may have no effect on another. Before treatment begins, specialists must determine whether a specific phage can successfully attack the bacteria causing a patient’s infection.
The new guidelines do not recommend phage therapy as a routine treatment. Instead, they emphasize careful evaluation of individual patients and use of the approach only when established treatments have failed, are unavailable, or cannot be used safely. Research suggests that properly manufactured and administered phages generally have a favorable safety profile, though controlled clinical trials have not yet provided sufficient evidence to establish reliability.
Implementation and Clinical Standards
A central challenge in personalized phage therapy is finding the correct virus for each patient. Laboratories must test candidate viruses to ensure they can kill the specific bacterial strain involved. This process, known as a phage match, should be completed quickly because bacteria can change their susceptibility during an infection. If multiple pathogens are present, specialists should test all relevant organisms.
The guidelines recommend that treatment decisions involve a collaborative team, including the patient’s physicians, clinical microbiologists, and recognized phage experts. They also establish expectations for cooperation among laboratories, manufacturing facilities, pharmacies, and clinical teams. Consistent testing methods and regular proficiency assessments are required to ensure results from different facilities are reliable.
Dr. Annika Claßen, a researcher with the German Center for Infection Research (DZIF) and director of the Translational Bacteriophage Research Group at University Hospital Cologne, played a leading role in developing the recommendations. She emphasized that standardizing quality criteria for phage production and identifying infrastructural requirements are essential for reliable treatments.
Other major contributors include PD Dr. Silvia Wörstle, Prof. Maria Vehreschild, and Dr. Simone Lieberknecht-Jouy of Goethe University Frankfurt. Wörstle, the corresponding author of the guideline, stated that the document provides a common framework for physicians, pharmacists, and regulatory authorities to incorporate phage therapy safely.
Early Clinical Results and Future Research
Early clinical experiences suggest the treatment could benefit some patients with difficult infections. In a Belgian case series involving 100 people, 77 percent experienced an improvement in their clinical condition. In 61 percent of cases, tests could no longer detect the targeted bacteria. However, observational studies cannot establish whether phages were responsible for these improvements or how well the treatment would perform in controlled trials.
At Frankfurt University Medical Center, Wörstle is overseeing the development of facilities and procedures to provide phage therapy according to the new recommendations. The medical center reports that ten patients have been successfully treated through its program since February 2026. The treatments targeted pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus, which are often challenging to manage due to antibiotic resistance.
Delivery methods vary depending on the infection and patient needs. Treatments may involve intravenous administration, inhalation, nasal spray, or application through a sterile hydrogel. The guidelines call for systematic documentation of every treatment in registries to allow researchers to compare experiences and investigate unanswered questions. Larger, carefully designed studies are needed to clarify effectiveness and identify which patients are most likely to benefit.
Source: ScienceDaily
